zacks.com / .zacks-com / Page 10

Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains.

In Trump's second term, tech giants like GOOGL, MSFT, META and AAPL face tough regulations on AI, antitrust and privacy.

TUYA's diverse portfolio and strong clientele make the stock lucrative. However, stretched valuation and macro headwinds can be risky.

With FDX looking to cut costs in the face of weak demand, we aim to assess the investment worthiness of the stock currently.

MS stock gains 32.4% this year. With the revival of global M&As, read on to know how 2025 will be for the stock and what investors should do.

ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This results in a decline in the company's revenues.

In a row of sequential acquisitions, FCPT adds nine more healthcare properties, broadening its portfolio.

GD secures a contract to provide engineering, technical, design agent and planning yard support for operational strategic and attack submarines.

ACM strengthens its leadership in the U.K. water sector with key AMP8 contract wins.

As consumer preferences continue to evolve toward health and value-driven purchases, TSN, STZ, FRPT, PG and CL are well-placed for growth in 2025.